Product Description: Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC50 of 8.05 nM and low oral bioavailability. Enpp-1-IN-25 can effectively activate the intracellular STING pathway by inhibiting cGAMP degradation. Enpp-1-IN-25 can enhance immune cell infiltration in the tumor microenvironment and type I interferon responses, and potentiate the antitumor efficacy of the anti-PD-L1 antibody. Enpp-1-IN-25 can be used in the research of cancer immunotherapy[1].
Formula: C15H21N5O4S
References: [1]He J, et al. Design, Synthesis, and Pharmacological Evaluation of Quinazoline and Quinoline Derivatives as Potent ENPP1 Inhibitors for Cancer Immunotherapy. J Med Chem. 2025 Feb 20.
CAS Number: 3067908-20-4
Molecular Weight: 367.42
Research Area: Cancer
Target: PD-1/PD-L1;Phosphodiesterase (PDE);STING